Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline

Karam Mounzer, Jihad Slim, Moti Ramgopal, Malcolm Hedgcock, Mark Bloch, Jorge Santana, Keith Aizen, Xu Zhang, Peter Sklar, Jairo M Montezuma-Rusca, Sorana Segal-Maurer

Open source

DOI
10.1093/ofid/ofaf615
Published
2025-10-06
Container
Open Forum Infectious Diseases
Publisher
Oxford University Press (OUP)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/ofid/ofaf615,
  title = {Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline},
  author = {Karam Mounzer and Jihad Slim and Moti Ramgopal and Malcolm Hedgcock and Mark Bloch and Jorge Santana and Keith Aizen and Xu Zhang and Peter Sklar and Jairo M Montezuma-Rusca and Sorana Segal-Maurer},
  year = {2025},
  journal = {Open Forum Infectious Diseases},
  doi = {10.1093/ofid/ofaf615},
  url = {https://doi.org/10.1093/ofid/ofaf615}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline
AU  - Karam Mounzer
AU  - Jihad Slim
AU  - Moti Ramgopal
AU  - Malcolm Hedgcock
AU  - Mark Bloch
AU  - Jorge Santana
AU  - Keith Aizen
AU  - Xu Zhang
AU  - Peter Sklar
AU  - Jairo M Montezuma-Rusca
AU  - Sorana Segal-Maurer
PY  - 2025
JO  - Open Forum Infectious Diseases
DO  - 10.1093/ofid/ofaf615
UR  - https://doi.org/10.1093/ofid/ofaf615
ER  - 

APA

Mounzer, K., Slim, J., Ramgopal, M., Hedgcock, M., Bloch, M., Santana, J., Aizen, K., Zhang, X., Sklar, P., Montezuma-Rusca, J. M., & Segal-Maurer, S. (2025). Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofaf615

Source records